DIMENSIONAL FUND ADVISORS LP
Position in DNTH — Dianthus Therapeutics, Inc. /DE/
CIK 354204
AUSTIN, TX
Position in DNTH
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$27,310,922
+$18,629,090 QoQ
Shares Held
325,440
+54.5% QoQ
Ownership
0.595%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
6 quarters on record
Voting authority
Sole 90.79891838741396.ToString("F0")%
Shared 5.911688790560472.ToString("F0")%
None 3.2893928220255657.ToString("F0")%
Common Shares in DNTH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026DIMENSIONAL FUND ADVISORS LP holds $5,003,215,874 across 223 Biotechnology names. DNTH ranks #46 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
989,342 | $441,780,774 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
513,060 | $396,410,676 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,895,215 | $358,290,394 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
3,802,930 | $214,827,514 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
7,475,866 | $207,081,486 | |
| 6 | INCY |
Incyte Corp
|
1,975,544 | $185,938,199 | |
| 7 | EXEL |
Exelixis, Inc.
|
4,299,597 | $184,409,714 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
2,079,827 | $134,419,216 |
All Filings in DNTH
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $27,310,922 | 325,440 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $8,681,832 | 210,673 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $341,911 | 8,689 | Shares | Sole | 2025-11-12 | |
| 2024-06-30 | $510,508 | 19,726 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | $651,840 | 21,728 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $153,254 | 14,736 | Shares | Sole | 2024-02-07 | |
| No filing history on record for this holder in this stock. | ||||||